OREANDA-NEWS. May 24, 2011. Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and AstraZeneca KK (an affiliate of AstraZeneca PLC; hereafter AstraZeneca) today announced a co-promotion agreement in Japan for Denosumab for the treatment of bone disorders stemming from bone metastasis.

Denosumab is the world’s first fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Daiichi Sankyo acquired Denosumab right in 2007 from Amgen Inc., and filed a Japanese New Drug Application (JNDA) for it in August 2010.